UA76463C2 - Pharmaceutical dosage form of amorphous nelfinavir mesylate - Google Patents

Pharmaceutical dosage form of amorphous nelfinavir mesylate Download PDF

Info

Publication number: UA76463C2
Authority: UA; Ukraine
Prior art keywords: nelfinavir mesylate; dosage form; form according; copolymer; nelfinavir
Prior art date: 2001-05-03

Application number

UA20031210981A

Other languages

English (en)

Ukrainian (uk)

Inventor

Howard Infeld

Hargovindas Shah

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-03

Filing date

2002-04-29

Publication date

2006-08-15

2002-04-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-08-15 Publication of UA76463C2 publication Critical patent/UA76463C2/uk

Links

229960005230 nelfinavir mesylate Drugs 0.000 title claims abstract description 77
NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 title claims abstract description 77
239000002552 dosage form Substances 0.000 title claims abstract description 16
229920001577 copolymer Polymers 0.000 claims abstract description 21
239000007787 solid Substances 0.000 claims abstract description 20
229920001400 block copolymer Polymers 0.000 claims abstract description 19
238000002844 melting Methods 0.000 claims abstract description 18
230000008018 melting Effects 0.000 claims abstract description 18
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 11
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims abstract description 9
239000003826 tablet Substances 0.000 claims description 54
239000000203 mixture Substances 0.000 claims description 36
239000008187 granular material Substances 0.000 claims description 20
239000000155 melt Substances 0.000 claims description 12
239000012458 free base Substances 0.000 claims description 10
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 9
229960000884 nelfinavir Drugs 0.000 claims description 9
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 9
238000010438 heat treatment Methods 0.000 claims description 6
238000012545 processing Methods 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
239000000945 filler Substances 0.000 claims description 5
238000000354 decomposition reaction Methods 0.000 claims description 4
239000007884 disintegrant Substances 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
239000003381 stabilizer Substances 0.000 claims description 3
239000000080 wetting agent Substances 0.000 claims description 3
239000007894 caplet Substances 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
101800001776 Nuclear inclusion protein B Proteins 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
238000007909 melt granulation Methods 0.000 abstract description 9
239000012943 hotmelt Substances 0.000 abstract description 5
238000004090 dissolution Methods 0.000 description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
229940079593 drug Drugs 0.000 description 12
239000003814 drug Substances 0.000 description 12
235000019359 magnesium stearate Nutrition 0.000 description 7
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
239000006186 oral dosage form Substances 0.000 description 5
229920001983 poloxamer Polymers 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
239000008190 ground granulate Substances 0.000 description 4
229940126601 medicinal product Drugs 0.000 description 4
239000008213 purified water Substances 0.000 description 4
238000005550 wet granulation Methods 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
239000000378 calcium silicate Substances 0.000 description 3
229910052918 calcium silicate Inorganic materials 0.000 description 3
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
229960000913 crospovidone Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000001087 glyceryl triacetate Substances 0.000 description 3
235000013773 glyceryl triacetate Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
229940124531 pharmaceutical excipient Drugs 0.000 description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
229960002622 triacetin Drugs 0.000 description 3
ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 2
229920005682 EO-PO block copolymer Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
235000012241 calcium silicate Nutrition 0.000 description 2
239000006255 coating slurry Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000011874 heated mixture Substances 0.000 description 2
238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 2
239000008023 pharmaceutical filler Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229960000502 poloxamer Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
-1 polyoxyethylene Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229950003441 tebufelone Drugs 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
101100187130 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nim-1 gene Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001760 anti-analgesic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000004174 erythrosine Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000036737 immune function Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
239000007962 solid dispersion Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA20031210981A 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate UA76463C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28841001P	2001-05-03	2001-05-03
PCT/EP2002/004711 WO2002089835A2 (fr)	2001-05-03	2002-04-29	Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe

Publications (1)

Publication Number	Publication Date
UA76463C2 true UA76463C2 (en)	2006-08-15

Family

ID=23106974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031210981A UA76463C2 (en)	2001-05-03	2002-04-29	Pharmaceutical dosage form of amorphous nelfinavir mesylate

Country Status (36)

Country	Link
US (1)	US7014866B2 (fr)
EP (1)	EP1390063B1 (fr)
JP (1)	JP4101661B2 (fr)
KR (1)	KR100554816B1 (fr)
CN (1)	CN1255185C (fr)
AR (1)	AR034320A1 (fr)
AT (1)	ATE282428T1 (fr)
BG (1)	BG108311A (fr)
BR (1)	BR0209325A (fr)
CA (1)	CA2444116C (fr)
CZ (1)	CZ20033211A3 (fr)
DE (1)	DE60201988T2 (fr)
EA (1)	EA006627B1 (fr)
EC (1)	ECSP034827A (fr)
ES (1)	ES2231717T3 (fr)
GE (1)	GEP20053466B (fr)
GT (1)	GT200200079A (fr)
HR (1)	HRP20030873B1 (fr)
HU (1)	HU229938B1 (fr)
IL (2)	IL158306A0 (fr)
IS (1)	IS7010A (fr)
JO (1)	JO2401B1 (fr)
MA (1)	MA27018A1 (fr)
MX (1)	MXPA03009971A (fr)
MY (1)	MY128509A (fr)
NO (1)	NO20034689D0 (fr)
NZ (1)	NZ528689A (fr)
PA (1)	PA8544501A1 (fr)
PE (1)	PE20021159A1 (fr)
PL (1)	PL366998A1 (fr)
PT (1)	PT1390063E (fr)
RS (1)	RS83503A (fr)
SK (1)	SK14572003A3 (fr)
TW (1)	TWI234461B (fr)
UA (1)	UA76463C2 (fr)
WO (1)	WO2002089835A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1175205B1 (fr)	1999-11-12	2006-06-14	Abbott Laboratories	Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
DE10026698A1 (de)	2000-05-30	2001-12-06	Basf Ag	Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (fr) *	2002-01-28	2003-07-28	Pfizer Inc.	Comprime de nelfinavir a dose elevee et methode de production connexe
CN100475209C (zh) *	2003-07-15	2009-04-08	阿利健制药有限公司	抗冠状病毒剂
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
JP2007517016A (ja) *	2003-12-31	2007-06-28	ファイザー・プロダクツ・インク	低溶解性薬剤及びポロキサマーの固体組成物
EP2586444B1 (fr) *	2004-12-03	2019-09-25	Merck Sharp & Dohme Corp.	Formulation pharmaceutique d'inhibiteurs de l'intégrase du VIH de type carboxamide contenant une composition de contrôle de vitesse de libération
SI1928427T1 (sl) *	2005-09-23	2010-03-31	Hoffmann La Roche	Nove formulacije za doziranje
KR20080089344A (ko) *	2005-12-14	2008-10-06	에프. 호프만-라 로슈 아게	Ｃ형 간염 바이러스(ｈｃｖ) 전구약물 제형
ES2350497T3 (es) *	2005-12-14	2011-01-24	F. Hoffmann-La Roche Ag	Formulación de profármacos para el vhc.
PE20080422A1 (es) *	2006-08-10	2008-04-28	Cipla Ltd	Composicion solida antirretroviral de administracion oral
US20100038816A1 (en) *	2006-08-16	2010-02-18	Novartis Ag	Method of making solid dispersions of highly crystalline therapeutic compounds
EP2112925A4 (fr) *	2006-11-15	2013-01-09	Abbott Lab	Formulations de dosage pharmaceutique solides
WO2008115442A1 (fr)	2007-03-16	2008-09-25	Concert Pharmceuticals, Inc.	Inhibiteurs de protéine de transfert d'ester de cholestérol
KR20100012031A (ko) *	2007-04-19	2010-02-04	콘서트 파마슈티컬즈, 인크.	중수소화된 모르폴리닐 화합물
WO2008133949A1 (fr)	2007-04-25	2008-11-06	Concert Pharmaceuticals, Inc.	Analogues de cilostazol
US9194512B2 (en)	2007-04-30	2015-11-24	Mark Andreychuk	Coiled tubing with heat resistant conduit
US8567657B2 (en) *	2007-04-30	2013-10-29	Mtj Consulting Services Inc.	Coiled tubing with retainer for conduit
US7608737B2 (en)	2007-05-01	2009-10-27	Concert Pharmaceuticasl Inc.	Naphthyl(ethyl)acetamides
MX341177B (es)	2007-05-01	2016-08-10	Concert Pharmaceuticals Inc	Compuestos de morfina.
CN102964302B (zh)	2007-05-01	2015-10-21	康塞特医药品公司	吗啡烷化合物
PL3825306T3 (pl)	2007-05-01	2023-09-11	Sun Pharmaceutical Industries, Inc.	Związki morfinanu
WO2008156632A1 (fr)	2007-06-12	2008-12-24	Concert Pharmaceuticals, Inc.	Dérivés d'azapeptides
WO2009051782A1 (fr) *	2007-10-18	2009-04-23	Concert Pharmaceuticals Inc.	Étravirine deutérée
CA2702935A1 (fr) *	2007-10-19	2009-04-23	Purdue Research Foundation	Formulations solides de composes cristallins
ITMI20080227A1 (it) *	2008-02-13	2009-08-14	Felice Vinati	'' dispositivo di sicurezza per apparati di sollevamento a fune ''
AU2009217680B2 (en)	2008-02-29	2013-09-05	Concert Pharmaceuticals, Inc	Substituted xanthine derivatives
US20110160253A1 (en) *	2008-05-28	2011-06-30	Harbeson Scott L	Deuterated tizanidine
WO2010019557A1 (fr) *	2008-08-12	2010-02-18	Concert Pharmaceuticals Inc.	Dérivés n-phényl-2-pyrimidineamine
DK3248978T3 (da)	2008-09-19	2019-11-18	Concert Pharmaceuticals Inc	Deutererede morphinanforbindelser
PL2397158T3 (pl)	2008-10-30	2016-09-30		Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu
WO2010062690A1 (fr)	2008-10-30	2010-06-03	Concert Pharmaceuticals Inc.	Combinaison de composés de morphinane et d’antidépresseur pour le traitement de l’affect pseudobulbaire, des maladies neurologiques, de la douleur incurable et chronique et des lésions cérébrales
CN103396473A (zh)	2008-11-04	2013-11-20	安科治疗公司	Cxcr4受体化合物
US20110313004A1 (en)	2008-12-04	2011-12-22	Concert Pharmaceuticals, Inc.	Deuterated pyridinones
US20110053961A1 (en)	2009-02-27	2011-03-03	Concert Pharmaceuticals, Inc.	Substituted xanthine derivatives
US8563554B2 (en)	2009-03-17	2013-10-22	Concert Pharmaceuticals, Inc.	Deuterated pyrazinoisoquinoline compounds
US20120244122A1 (en)	2009-05-28	2012-09-27	Masse Craig E	Peptides for the Treatment of HCV Infections
EP2454259A1 (fr)	2009-06-23	2012-05-23	Concert Pharmaceuticals Inc.	Dérivés de triazolo-pyridazine modifiés par deutérium comme modulateurs du récepteur gaba-a
US20110015154A1 (en) *	2009-07-20	2011-01-20	Kellermann Gottfried H	Supporting acetylcholine function
WO2011047315A1 (fr)	2009-10-15	2011-04-21	Concert Pharmaceuticals, Inc.	Benzimidazoles substitués
US20110098265A1 (en) *	2009-10-28	2011-04-28	Neuroscience, Inc.	Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (fr)	2009-11-12	2011-05-19	Concert Pharmaceuticals Inc.	Azaindoles substitués
EP2536696A1 (fr)	2010-02-18	2012-12-26	Concert Pharmaceuticals Inc.	Dérivés de la pyrimidine
EP2566494B1 (fr)	2010-02-26	2017-11-29	Acer Therapeutics, Inc.	Composés de récepteur cxcr4
EP2542534A1 (fr)	2010-03-02	2013-01-09	Concert Pharmaceuticals Inc.	Dérivés de tétrahydronaphtalène deutérés
US8575361B2 (en)	2010-03-02	2013-11-05	Concert Pharmaceuticals Inc.	Tetrahydronaphthalene derivatives
US20130116239A1 (en)	2010-06-14	2013-05-09	ratiopharm GnbH	Ivabradine-containing pharmaceutical composition with modified release
US20120208837A1 (en)	2010-09-13	2012-08-16	Roger Tung	Substituted azaindoles
EP2455068A1 (fr) *	2010-11-09	2012-05-23	F. Hoffmann-La Roche AG	Composition pharmaceutique pour le traitement d'infections par VHC
WO2012065028A2 (fr)	2010-11-11	2012-05-18	Concert Pharmaceuticals Inc.	Tétracyclines substituées
WO2012079075A1 (fr)	2010-12-10	2012-06-14	Concert Pharmaceuticals, Inc.	Dérivés de phtalimide deutérés
US8447329B2 (en)	2011-02-08	2013-05-21	Longsand Limited	Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja)	2011-02-25	2014-03-17	コンサートファーマシューティカルズインコーポレイテッド	２−アミノ−ナフチリジン誘導体
WO2012129381A1 (fr)	2011-03-22	2012-09-27	Concert Pharmaceuticals Inc.	Preladenant deutéré
WO2012151361A1 (fr)	2011-05-03	2012-11-08	Concert Pharmaceuticals Inc.	Dérivés de carbamoylpyridone
US20140128469A1 (en)	2011-05-10	2014-05-08	Concert Pharmaceuticals Inc.	Deuterated n-butyl bumetanide
PL2709986T3 (pl)	2011-05-18	2017-09-29	Concert Pharmaceuticals Inc.	Deuterowane pochodne iwakaftoru
US20140296263A1 (en)	2011-07-19	2014-10-02	Concert Pharmaceuticals, Inc.	Substituted xanthine derivatives
FR2985177B1 (fr) *	2012-01-02	2016-04-01	Oreal	Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
CA2860740A1 (fr)	2012-01-09	2013-07-18	Anchor Therapeutics, Inc.	Composes de recepteurs apj
WO2013130849A1 (fr)	2012-02-29	2013-09-06	Concert Pharmaceuticals, Inc.	Dérivés de phthalimide dioxopipéridinyle substitués
EP2836492B1 (fr)	2012-04-13	2018-03-14	Concert Pharmaceuticals Inc.	Dérivés de xanthine substituée
WO2013159026A1 (fr)	2012-04-20	2013-10-24	Concert Pharmaceuticals, Inc.	Rigosertib deutéré
ES2867048T3 (es)	2012-06-15	2021-10-20	Concert Pharmaceuticals Inc	Derivados deuterados de ruxolitinib
CA2908929C (fr)	2012-07-12	2021-01-26	Concert Pharmaceuticals, Inc.	Idebenone deuteree
BR112015003153A2 (pt)	2012-08-17	2017-07-04	Concert Pharmaceuticals Inc	baricitinib deuterado
WO2014078842A1 (fr)	2012-11-19	2014-05-22	Concert Pharmaceuticals, Inc.	Potentialisateurs de cftr deutérés
US20150299166A1 (en)	2012-12-20	2015-10-22	Concert Pharmaceuticals, Inc.	Deuterated alk inhibitors
US9789126B2 (en)	2012-12-21	2017-10-17	Mayo Foundation For Medical Education And Research	Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (fr)	2013-01-11	2014-07-17	Concert Pharmaceuticals, Inc.	Dérivés substitués de dioxopipéridinyl phtalimide
WO2014150043A1 (fr)	2013-03-15	2014-09-25	Concert Pharmaceuticals Inc.	Inhibiteurs de l'enzyme udp-glucose : n-acyl-sphingosine glucosyltransférase
AU2014235462C1 (en)	2013-03-15	2018-11-01	Concert Pharmaceuticals, Inc.	Deuterated palbociclib
HU231191B1 (hu)	2013-04-15	2021-08-30	Szegedi Tudományegyetem	Izotóp tartalmú morfin molekulák
WO2015009889A1 (fr)	2013-07-18	2015-01-22	Concert Pharmaceuticals, Inc.	Dérivés deutériés d'intédanib et leur utilisation pour le traitement de troubles prolifératifs
WO2015010045A1 (fr)	2013-07-18	2015-01-22	Anchor Therapeutics, Inc.	Composés de récepteurs apj
WO2015031741A1 (fr)	2013-08-30	2015-03-05	Concert Pharmaceuticals, Inc.	Thiénotriazolodiazépines substituées
JP6526060B2 (ja)	2014-02-10	2019-06-05	コンサートファーマシューティカルズインコーポレイテッド	置換トリアゾロベンゾジアゼピン
US20170216296A1 (en)	2014-04-18	2017-08-03	Concert Pharmaceuticals, Inc.	Methods of treating hyperglycemia
WO2015179772A1 (fr)	2014-05-23	2015-11-26	Concert Pharmaceuticals, Inc.	Composés phénylquinazolinone et phénylisoquinolinone deutérés
CN106459004B (zh)	2014-06-06	2020-09-15	研究三角协会	爱帕琳肽受体(apj)激动剂及其用途
WO2016022955A1 (fr)	2014-08-07	2016-02-11	Mayo Foundation For Medical Education And Research	Composés et méthodes de traitement du cancer
WO2016061488A1 (fr)	2014-10-17	2016-04-21	Concert Pharmaceuticals, Inc.	Inhibiteurs de réabsorption d'amines
WO2016073545A1 (fr)	2014-11-06	2016-05-12	Concert Pharmaceuticals, Inc.	Acides benzoïques de phényloxadiazole
WO2016089814A1 (fr)	2014-12-02	2016-06-09	Concert Pharmaceuticals, Inc.	Analogues deutériés du daclatasvir
WO2016094011A1 (fr) *	2014-12-11	2016-06-16	Merck Sharp & Dohme Corp.	Formes cristallines d'un antagoniste de ccr5
CN105769809A (zh) *	2014-12-23	2016-07-20	上海星泰医药科技有限公司	提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (fr)	2014-12-24	2016-06-30	Concert Pharmaceuticals, Inc.	Dasabuvir deutéré
WO2016109795A1 (fr)	2014-12-31	2016-07-07	Concert Pharmaceuticals, Inc.	Funapide et difluorofunapide deutérés
EP3265440A1 (fr)	2015-03-06	2018-01-10	Concert Pharmaceuticals Inc.	Emricasan deutéré
WO2016160945A1 (fr)	2015-03-31	2016-10-06	Concert Pharmaceuticals, Inc.	Vx-661 deutéré
WO2016176335A1 (fr)	2015-04-27	2016-11-03	Concert Pharmaceuticals, Inc.	Otx-015 deutéré
WO2017020005A1 (fr)	2015-07-30	2017-02-02	Concert Pharmaceuticals, Inc.	Composés de morphinane utilisés pour le traitement de l'agitation
US20180243289A1 (en)	2015-07-30	2018-08-30	Concert Pharmaceuticals, Inc.	Deuterated morphinan compounds for treating agitation
US20180353500A1 (en)	2015-09-21	2018-12-13	Vertex Pharmaceuticals (Europe) Limited	Administration of deuterated cftr potentiators
EP3377179B1 (fr)	2015-11-19	2021-04-07	Concert Pharmaceuticals Inc.	Epi-743 deutéré
PE20190258A1 (es)	2015-12-09	2019-02-25	Res Triangle Inst	Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
WO2017147003A1 (fr)	2016-02-26	2017-08-31	Novobiotic Pharmaceuticals, Llc	Nouveaux antibiotiques macrocycliques et leurs utilisations
HRP20241345T1 (hr)	2016-05-04	2024-12-20	Sun Pharmaceutical Industries, Inc.	Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak
PT3825307T (pt)	2016-07-04	2022-08-26	Avanir Pharmaceuticals Inc	Métodos para a síntese de dextrometorfano deuterado
EP3490538A4 (fr)	2016-08-01	2020-03-18	The Brigham and Women's Hospital, Inc.	Particules pour l'administration de protéines et de peptides
WO2018119076A1 (fr)	2016-12-21	2018-06-28	Research Triangle Institute	Dérivés de diarylpurine présentant une biodisponibilité améliorée
ES3036483T3 (en)	2017-02-28	2025-09-19	Mayo Found Medical Education & Res	Combinations for use in the treatment of cancer
US11278025B2 (en)	2017-05-17	2022-03-22	The General Hospital Corporation	Antibiotic compounds
CA3063953A1 (fr)	2017-05-19	2018-11-22	Superb Wisdom Limited	Derives de resiquimod
AU2018371784B2 (en)	2017-11-22	2024-10-17	Sun Pharmaceutical Industries, Inc.	Deuterated analogs of D-serine and uses thereof
US11243207B2 (en)	2018-03-29	2022-02-08	Mayo Foundation For Medical Education And Research	Assessing and treating cancer
KR20210150495A (ko)	2019-04-10	2021-12-10	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
WO2021236139A1 (fr)	2020-05-21	2021-11-25	Concert Pharmaceuticals, Inc.	Nouvel inhibiteur de jak deutéré et ses utilisations
WO2021243015A1 (fr)	2020-05-27	2021-12-02	The Penn State Research Foundation	Composés antibactériens
EP4236956A1 (fr)	2020-10-28	2023-09-06	Sun Pharmaceutical Industries, Inc.	Régimes pour le traitement de troubles liés à la perte des cheveux avec des inhibiteurs de jak deutérés
AU2022225215A1 (en)	2021-02-25	2023-08-31	Research Triangle Institute	Heteroaryl derivatives as apelin receptor agonists
AU2022328272A1 (en)	2021-08-11	2024-02-22	Sun Pharmaceutical Industries, Inc.	Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (fr)	2021-08-12	2023-02-16	Concert Pharmaceuticals, Inc.	Traitement de troubles sensibles à l'inhibition de jak avec des promédicaments d'inhibiteurs de jak
US20250275977A1 (en)	2022-05-04	2025-09-04	Sun Pharmaceutical Industries, Inc.	Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5281420A (en) *	1992-05-19	1994-01-25	The Procter & Gamble Company	Solid dispersion compositions of tebufelone
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
US5834472A (en) *	1996-05-24	1998-11-10	Schering Corporation	Antifungal composition with enhanced bioavailability
US6232333B1 (en) *	1996-11-21	2001-05-15	Abbott Laboratories	Pharmaceutical composition
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) *	1997-03-13	1999-12-14	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
ES2248908T7 (es) *	1997-06-06	2014-11-24	Depomed, Inc.	Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
WO1998057648A1 (fr) *	1997-06-16	1998-12-23	Vertex Pharmaceuticals Incorporated	Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose
EP1028712B1 (fr) *	1997-09-19	2005-01-12	Shire Laboratories Inc.	Granule de solution solide
ES2235991T3 (es) *	1999-11-12	2005-07-16	Abbott Laboratories	Formulaciones farmaceuticas de dispersion solida.
US6499984B1 (en) *	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation

2002
- 2002-04-29 BR BR0209325-1A patent/BR0209325A/pt not_active Application Discontinuation
- 2002-04-29 ES ES02748680T patent/ES2231717T3/es not_active Expired - Lifetime
- 2002-04-29 GE GE5295A patent/GEP20053466B/en unknown
- 2002-04-29 NZ NZ528689A patent/NZ528689A/en unknown
- 2002-04-29 HR HR20030873A patent/HRP20030873B1/xx not_active IP Right Cessation
- 2002-04-29 RS YU83503A patent/RS83503A/sr unknown
- 2002-04-29 PL PL02366998A patent/PL366998A1/xx unknown
- 2002-04-29 JP JP2002586967A patent/JP4101661B2/ja not_active Expired - Fee Related
- 2002-04-29 MX MXPA03009971A patent/MXPA03009971A/es active IP Right Grant
- 2002-04-29 HU HU0401238A patent/HU229938B1/hu not_active IP Right Cessation
- 2002-04-29 UA UA20031210981A patent/UA76463C2/uk unknown
- 2002-04-29 PT PT02748680T patent/PT1390063E/pt unknown
- 2002-04-29 KR KR1020037014234A patent/KR100554816B1/ko not_active Expired - Fee Related
- 2002-04-29 WO PCT/EP2002/004711 patent/WO2002089835A2/fr not_active Ceased
- 2002-04-29 SK SK1457-2003A patent/SK14572003A3/sk unknown
- 2002-04-29 DE DE60201988T patent/DE60201988T2/de not_active Expired - Lifetime
- 2002-04-29 EP EP02748680A patent/EP1390063B1/fr not_active Expired - Lifetime
- 2002-04-29 EA EA200301166A patent/EA006627B1/ru not_active IP Right Cessation
- 2002-04-29 CZ CZ20033211A patent/CZ20033211A3/cs unknown
- 2002-04-29 AT AT02748680T patent/ATE282428T1/de active
- 2002-04-29 IL IL15830602A patent/IL158306A0/xx unknown
- 2002-04-29 CA CA002444116A patent/CA2444116C/fr not_active Expired - Fee Related
- 2002-04-29 CN CNB028092953A patent/CN1255185C/zh not_active Expired - Fee Related
- 2002-04-30 PE PE2002000369A patent/PE20021159A1/es not_active Application Discontinuation
- 2002-04-30 TW TW091108967A patent/TWI234461B/zh not_active IP Right Cessation
- 2002-04-30 AR ARP020101580A patent/AR034320A1/es not_active Application Discontinuation
- 2002-04-30 MY MYPI20021591A patent/MY128509A/en unknown
- 2002-04-30 PA PA20028544501A patent/PA8544501A1/es unknown
- 2002-05-01 JO JO200237A patent/JO2401B1/en active
- 2002-05-02 US US10/138,071 patent/US7014866B2/en not_active Expired - Fee Related
- 2002-05-02 GT GT200200079A patent/GT200200079A/es unknown
2003
- 2003-10-08 IL IL158306A patent/IL158306A/en not_active IP Right Cessation
- 2003-10-20 NO NO20034689A patent/NO20034689D0/no not_active Application Discontinuation
- 2003-10-30 IS IS7010A patent/IS7010A/is unknown
- 2003-10-31 EC EC2003004827A patent/ECSP034827A/es unknown
- 2003-11-03 MA MA27379A patent/MA27018A1/fr unknown
- 2003-11-03 BG BG108311A patent/BG108311A/bg unknown

Also Published As

Publication number	Publication date
CZ20033211A3 (cs)	2004-09-15
MA27018A1 (fr)	2004-12-20
HRP20030873B1 (en)	2006-04-30
IL158306A (en)	2008-11-03
SK14572003A3 (sk)	2004-12-01
US20030021840A1 (en)	2003-01-30
HRP20030873A2 (en)	2005-08-31
JP4101661B2 (ja)	2008-06-18
AR034320A1 (es)	2004-02-18
PE20021159A1 (es)	2002-12-20
TWI234461B (en)	2005-06-21
PL366998A1 (en)	2005-02-07
CA2444116C (fr)	2009-01-20
JP2004527569A (ja)	2004-09-09
EP1390063B1 (fr)	2004-11-17
CN1255185C (zh)	2006-05-10
BG108311A (bg)	2004-12-30
BR0209325A (pt)	2004-07-20
CA2444116A1 (fr)	2002-11-14
ES2231717T3 (es)	2005-05-16
KR100554816B1 (ko)	2006-02-22
HUP0401238A3 (en)	2012-09-28
NO20034689L (no)	2003-10-20
NZ528689A (en)	2005-03-24
WO2002089835A3 (fr)	2003-05-01
HU229938B1 (en)	2015-01-28
GEP20053466B (en)	2005-02-25
KR20040007523A (ko)	2004-01-24
DE60201988T2 (de)	2005-12-15
PT1390063E (pt)	2005-03-31
IL158306A0 (en)	2004-05-12
PA8544501A1 (es)	2002-11-18
DE60201988D1 (de)	2004-12-23
EP1390063A2 (fr)	2004-02-25
IS7010A (is)	2003-10-30
US7014866B2 (en)	2006-03-21
HUP0401238A2 (hu)	2004-12-28
JO2401B1 (en)	2007-06-17
CN1547484A (zh)	2004-11-17
GT200200079A (es)	2002-12-05
EA200301166A1 (ru)	2004-04-29
ECSP034827A (es)	2003-12-24
HK1070285A1 (en)	2005-06-17
ATE282428T1 (de)	2004-12-15
WO2002089835A2 (fr)	2002-11-14
NO20034689D0 (no)	2003-10-20
MXPA03009971A (es)	2004-02-12
MY128509A (en)	2007-02-28
EA006627B1 (ru)	2006-02-24
RS83503A (sr)	2006-10-27

Publication	Publication Date	Title
UA76463C2 (en)	2006-08-15	Pharmaceutical dosage form of amorphous nelfinavir mesylate
US6291462B1 (en)	2001-09-18	Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
CA2435714C (fr)	2011-02-22	Comprimes de fenofibrate
KR20150015500A (ko)	2015-02-10	엔테카비어의 약제학적 조성물 및 제조 방법
JP2010280707A (ja)	2010-12-16	メシル酸サキナビル経口投与剤型
JPH0717866A (ja)	1995-01-20	医薬組成物
JP2010534222A (ja)	2010-11-04	ダルナビルを含んでなる抗ｈｉｖ錠剤製剤
JPH1121236A (ja)	1999-01-26	ロキソプロフェン・ナトリウム固形製剤
JP3837062B2 (ja)	2006-10-25	難溶性薬物を含有する複合粒固形製剤
JP4572296B2 (ja)	2010-11-04	ピモベンダン経口投与製剤
AU2002319154B2 (en)	2007-03-08	Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2005060310A (ja)	2005-03-10	不快な味をマスキングする経口投与用製剤
AU2002319154A1 (en)	2003-05-01	Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2005255595A (ja)	2005-09-22	ジオクチルソジウムスルホサクシネート配合錠剤
JPH0867631A (ja)	1996-03-12	ビタミンｅ含有内服剤用固形組成物
HK1070285B (en)	2006-08-18	Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2005015363A (ja)	2005-01-20	小型化クラリスロマイシン錠剤
HK1033281B (en)	2003-08-15	Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates